文献速递肺栓塞与肺血管病

肥胖改变雌激素代谢并促进肺动脉高压

Obesity alters oestrogen metabolism and contributes to pulmonary arterial hypertension.
PubMed 文献 · Eur Respir J · 2019-06-13

该研究在瘦素缺陷(ob/ob)肥胖小鼠中探究抑制雌激素合成与代谢对肺动脉高压的影响。结果显示肥胖小鼠自发产生肺动脉高压、肺血管重构和肺内活性氧增加,这些效应可被阿那曲唑或CYP1B1抑制剂TMS减轻;内脏脂肪组织可产生16αOHE1并参与氧化应激,提示雌激素抑制剂可能对肥胖PAH患者尤其有益。

要点

  • 肥胖小鼠自发肺动脉高压和肺血管重构,雌激素合成抑制剂阿那曲唑可减轻。
  • 肥胖小鼠内脏脂肪CYP1B1和16αOHE1升高,CYP1B1抑制剂TMS也减轻肺动脉高压。
  • 内脏脂肪条件培养基可产生16αOHE1并致氧化应激,阿那曲唑和TMS均可减轻。

核心结论

  • 肥胖可诱导肺动脉高压并改变雌激素代谢,使内脏脂肪组织产生更多16αOHE1,参与氧化应激。

研究设计与样本

  • 在雄性和雌性瘦素缺陷(ob/ob)肥胖小鼠中,分别用阿那曲唑抑制雌激素合成、用TMS抑制CYP1B1介导的雌激素代谢,观察肺动脉高压等指标。

主要发现

  • ob/ob小鼠自发出现肺动脉高压、肺血管重构和肺内活性氧产生增加,阿那曲唑可减轻这些效应。
  • 肥胖雄性小鼠血浆雌二醇降低,但内脏脂肪CYP1B1和尿16αOHE1升高;TMS也可减轻雄性ob/ob小鼠的肺动脉高压。
  • ob/ob小鼠胸腔内脂肪和内脏脂肪条件培养基可产生16αOHE1并促进氧化应激,阿那曲唑和TMS均可减轻。

临床怎么用

  • 雌激素抑制剂已进入PAH临床试验,本研究提示其可能对肥胖PAH个体尤其有益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Obesity is a common comorbidity for pulmonary arterial hypertension (PAH). Additionally, oestrogen and its metabolites are risk factors for the development of PAH. Visceral adipose tissue (VAT) is a major site of oestrogen production; however, the influence of obesity-induced changes in oestrogen synthesis and metabolism on the development of PAH is unclear. To address this we investigated the effects of inhibiting oestrogen synthesis and metabolism on the development of pulmonary hypertension in male and female obese mice.We depleted endogenous oestrogen in leptin-deficient (ob/ob) mice with the oestrogen inhibitor anastrozole (ANA) and determined the effects on the development of pulmonary hypertension, plasma oestradiol and urinary 16α-hydroxyestrone (16αOHE1). Oestrogen metabolism through cytochrome P450 1B1 (CYP1B1) was inhibited with 2,2',4,6'-tetramethoxystilbene (TMS).ob/ob mice spontaneously develop pulmonary hypertension, pulmonary vascular remodelling and increased reactive oxygen species production in the lung; these effects were attenuated by ANA. Oestradiol levels were decreased in obese male mice; however, VAT CYP1B1 and 16αOHE1 levels were increased. TMS also attenuated pulmonary hypertension in male ob/ob mice. Intra-thoracic fat from ob/ob mice and VAT conditioned media produce 16αOHE1 and can contribute to oxidative stress, effects that are attenuated by both ANA and TMS.Obesity can induce pulmonary hypertension and changes in oestrogen metabolism, resulting in increased production of 16αOHE1 from VAT that contributes to oxidative stress. Oestrogen inhibitors are now in clinical trials for PAH. This study has translational consequences as it suggests that oestrogen inhibitors may be especially beneficial in treating obese individuals with PAH.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Mair KM, Harvey KY, Henry AD, et al. Obesity alters oestrogen metabolism and contributes to pulmonary arterial hypertension. Eur Respir J. 2019. PMID: 30923189. doi:10.1183/13993003.01524-2018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。